Search the Newsreel

17,272,739 Common Stock of Liminatus Pharma, Inc. are subject to a Lock-Up Agreement Ending on 19-AUG-2026.

Liminatus Pharma, Inc. has 17,272,739 shares of common stock under a lock-up agreement that concludes on August 19, 2026. This agreement, spanning 182 days from February 18, 2026, restricts officers, directors, and significant stockholders from selling or disposing of company securities without Maxim's consent. …

Madrigal (NASDAQ: MDGL) awards Reed 647 RSUs and options on 1,078 shares

Madrigal Pharmaceuticals (NASDAQ: MDGL) director John C. Reed was granted 647 restricted stock units (RSUs) and options on 1,078 shares. The RSUs will vest 50% on August 15, 2027, and 50% on August 15, 2028, while the stock options, with an exercise price of …

Liminatus Pharma to implement 1-for-50 reverse stock split By Investing.com

Liminatus Pharma, Inc. announced a 1-for-50 reverse stock split of its common stock, effective at the close of trading on August 20, 2026. The split, approved by stockholders, will reduce the number of outstanding shares and aims to adjust the stock's trading price on …

What's Going On With Cipher Pharmaceuticals Inc Stock Tuesday?

Amylyx (AMLX) Climbs to Fresh High as Avexitide Moves Closer to Commercialization

Amylyx Pharmaceuticals (AMLX) stock surged to a new three-year high following strong Phase 3 clinical trial results for its drug candidate Avexitide, a treatment for post-bariatric hypoglycemia (PBH). The drug successfully reduced low-blood-sugar episodes by 55% and met all secondary endpoints, leading to increased …

Quantum (QNTM) Results Breakdown: The Latest Report Adds New Financial Reference Points under the Current Snapshot; Post-Earnings Trading: The Stock Records a 9.24% Decrease on the Day - Guidance Revision Trend

Aurinia (AUPH) Earnings Metrics: EPS Comes in Above Forecast in the Current Update; Trading-Day Reaction: Shares Move 0.07% Up - Quarterly Profit Report

Zenas BioPharma (ZBIO) Looks Pricey Following Weak Q2 Results And Leadership Changes

Supernus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SUPN)

BridgeBio (NASDAQ: BBIO) CEO has 71K RSUs vest, withholds shares for taxes

BridgeBio Pharma, Inc. CEO Neil Kumar had 71,217 Restricted Stock Units (RSUs) convert into common stock on August 16, 2026. To cover tax obligations from this vesting, 36,237 shares were withheld at $79.86 per share. Following these transactions, Kumar's indirect holdings across various trusts …

Recursion (NASDAQ: RXRX) CSO sees 26K shares withheld for taxes

Recursion Pharmaceuticals (NASDAQ: RXRX) Chief Scientific Officer David Hallett had 26,657 shares of Class A common stock withheld on August 17, 2026, to satisfy tax obligations related to the net settlement of restricted stock units. This action was solely for tax purposes and not …

Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock

Verrica Pharmaceuticals' (NASDAQ:VRCA) Chief Marketing Officer, Noah Rosenberg, purchased 4,200 shares of the company's stock for $20,622, increasing his direct ownership by 178.19%. This transaction occurred as VRCA shares traded down, below their 50-day and 200-day moving averages. The company holds an $80.4 million …

Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Acquires 5,000 Shares

Verrica Pharmaceuticals CEO Jayson Rieger recently purchased 5,000 shares of the company's stock for $24,550, increasing his total ownership to 207,593 shares. This transaction occurred as the stock fell 4.3% to $4.68, bringing its market capitalization to approximately $80.4 million. The company has mixed …

VRCA Looks 50.3% Undervalued on GF Value™ Despite Profitability Challenges

Verrica Pharmaceuticals Inc (NASDAQ: VRCA) saw its CEO purchase 25,000 shares, leading to a 7.5% after-hours price increase and renewed investor interest despite ongoing profitability challenges. While the GF Value™ suggests VRCA is 50.3% undervalued, this should be viewed cautiously given the company's negative …

Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors

Corbus Pharmaceuticals Holdings Inc. (CRBP) stock dropped 3.91% on Tuesday, closing at $10.08. This underperformance occurred during a general market downturn, with both the NASDAQ Composite Index and Dow Jones Industrial Average also experiencing losses. The decline ended a five-day winning streak for the …

Arrowhead (NASDAQ: ARWR) director to sell 2,000 shares

A director at Arrowhead Pharmaceuticals Inc. (ARWR), Adeoye Olukotun, has filed a Rule 144 notice to sell 2,000 shares of common stock through Merrill Lynch. The proposed sale, valued at $173,876.47, is expected around August 18, 2026, on NASDAQ. These shares were originally acquired …

Mirum Pharma (NASDAQ: MIRM) officer lines up $4M share sale

Jolanda Marie Howe, an officer at Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), has filed a Form 144 to sell 40,000 common shares valued at $4,000,000.00 on August 18, 2026, following a stock option exercise. The sale will be executed through Morgan Stanley Smith Barney. The …

Processa Pharmaceuticals (NASDAQ: PCSA) gains new 5.8% owner with no sole control

Soleus Capital Master Fund, L.P. and related entities, including Guy Levy, have reported a beneficial ownership of 160,943 shares of Processa Pharmaceuticals (PCSA), representing 5.8% of the outstanding common stock. This ownership grants shared voting and dispositive power but no sole control. The filing …

Silo Pharma receives Canadian patent allowance for SPC-15 drug By Investing.com

Silo Pharma has received a patent allowance from the Canadian Intellectual Property Office for its SPC-15 drug, an intranasal 5-HT4 receptor agonist designed to treat post-traumatic stress disorder and other stress-induced psychiatric conditions. The patent covers methods for preventing or delaying stress-induced fear and …

Rhythm (RYTM) CMO reports no company stock holdings

Rhythm Pharmaceuticals, Inc. (RYTM) Chief Medical Officer, Joshi Manher, has filed an initial statement of beneficial ownership (Form 3) indicating no equity transactions or holdings in the company. The filing includes an Exhibit 24 for a Power of Attorney, allowing filings to be made …

Rhythm Pharmaceuticals (RYTM) grants CMO 50K options expiring 2036

Rhythm Pharmaceuticals (RYTM) has granted its Chief Medical Officer, Manher Joshi, 50,000 stock options with an exercise price of $115.44, expiring in 2036, and 25,000 Restricted Stock Units (RSUs). The stock options vest over four years, while the RSUs vest annually from 2027 to …

Recursion Pharmaceuticals Inc (RXRX) News, Articles, Events & Latest Updates

MIRA (MIRA) Financial Results: The Company Lists Its Latest Available Figures in the Latest Session; Investor Response: Shares Fall 3.16% in the Latest Reading - Segment Revenue Breakdown

BioMarin looks to spur growth with potential $490M buyout of Dutch bone drug company

BioMarin Pharmaceutical is reportedly looking to acquire Dutch bone drug company Alesa Therapeutics for up to $490 million, including a $275 million upfront payment. This potential acquisition comes shortly after BioMarin decided to halt the late-stage development of another drug. The move is seen …

Verrica (NASDAQ: VRCA) CEO buys 25,000 shares in August

Verrica Pharmaceuticals Inc. (VRCA) CEO Jayson Rieger purchased 25,000 shares of common stock in August 2026. These open-market transactions included 5,000 shares bought on August 17 at $4.91 per share and 20,000 shares on August 14 at a weighted average price of $5.06. The …

Verrica (NASDAQ: VRCA) interim CFO adds 5,000 shares in open-market buy

Verrica Pharmaceuticals Inc.'s Interim CFO, John J. Kirby, purchased 5,000 shares of common stock in the open market on August 18, 2026. The shares were bought at a weighted average price of $4.93, with individual trades ranging from $4.85 to $4.99 per share. Following …

Cocrystal Pharma (NASDAQ: COCP) names Carol L. Brosgart to its board

Cocrystal Pharma, Inc. (NASDAQ: COCP) has appointed Carol L. Brosgart as a director to its Board, effective August 12, 2026. The company stated that there are no arrangements or understandings related to her selection, no family relationships with current directors or officers, and no …

Royalty Pharma (NASDAQ: RPRX) holder plans multi-million share sale

SCH Investment Partners LLC intends to sell 100,000 Class A Ordinary Shares of Royalty Pharma (NASDAQ: RPRX) with an aggregate market value of $6,012,000. These shares were acquired in private transactions in 2024 and 2025 and represent a small fraction of Royalty Pharma's 445,277,344 …

LUCIDITY Shows Clear Phase III Win For Amylyx’s Avexitide

Amylyx's Avexitide achieved a clear Phase III win in the LUCIDITY trial for patients with post-bariatric hypoglycemia (PBH). The company plans to submit the drug to the US FDA by the end of 2026. This positive outcome follows a previous late-stage drug failure for …

Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses

Lantern (LTRN) Reported Results Review: EPS Clears the Reported Estimate for the Current Session; Shares Move 3.08% Lower in the Latest Session - Non-GAAP Earnings

These 2 Stocks Are Setting Off Technical Alarm Bells with $1,000+ Price Tags. Here’s the Company I’d Bet on for the Long Term.

Buy Sell cards by Kelly Sikkema via Unsplash Virginia-based conglomerate Graham Holdings (GHC)was one of Barchart's 200 bearish price surprises in Monday trading. It was down 2.2% on the day to $1,165.29; its standard deviation was -1.67, far from the highest, Eyepoint (EYPT), at …

Liminatus Pharma Announced Transfer or Voluntary Withdrawal of Listing

Liminatus Pharma (LIMN) received approval from Nasdaq's Hearings Panel on July 31, 2026, to transfer to The Nasdaq Capital Market, effective August 4, 2026. This approval is contingent upon the company filing a transfer application by August 7 and maintaining a $1.00 closing bid …

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma announced inducement grants totaling 11,000 restricted stock units (RSUs) to newly hired employees. These grants, made on August 17, 2026, are a material inducement for employment, aligning with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal installments over a …

New Zenas BioPharma hires receive stock awards vesting through 2030

Zenas BioPharma announced on August 18, 2026, that its Board Compensation Committee granted 11,000 restricted stock units (RSUs) to newly hired employees as inducement awards. These RSUs, issued under Nasdaq Listing Rule 5635(c)(4) and the company’s 2026 Inducement Plan, will vest in four equal …

Rocket Pharma (NASDAQ: RCKT) sale tied to 2026 vesting, tax bill

Gaurav Shah, associated with Rocket Pharmaceuticals (RCKT), has filed a Rule 144 notice to sell 2,293 shares of restricted common stock. This proposed sale is linked to restricted stock vesting on August 14, 2026, and partially aims to cover a tax obligation from a …